Precision medicine allows treatments to be personalized to the person based on their genome. However, the majority of the studies lack diversity since they were mainly performed with European populations. The African American Cardiovascular Pharmacogenomics Consortium, or ACCOuNT, studies the response of medications in self-identified African American populations. This project involves performing proteome-wide (PWAS), genome-wide (GWAS), and transcriptome-wide (TWAS) association studies using the tools PrediXcan and GEMMA. The goal of this project was to study the effect of the anticoagulant medications, clopidogrel and NOAC, in relation to the phenotype creatinine clearance with the genetic diversity found in African American populations.